CGTX Cognition Therapeutics, Inc.
Listings ·
Nasdaq told Cognition Therapeutics on August 26, 2025 that the company again meets its listing requirements after the stock closed above $1.00 for more than ten trading days.
We have not published a story on Cognition Therapeutics yet. When there is news, it will appear here.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, zervimesine, also known as CT1812, is an orally delivered small molecule designed to prevent oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein, from binding to neurons. The company's initial focus was Alzheimer's disease. Its Phase 2 COG0201 (SHINE) study reported top-line results in 2024. The Phase 2 COG0203 (START) study in mild cognitive impairment and early-stage Alzheimer's disease completed enrollment in December 2025, with top-line results expected after all participants complete 18 months of treatment. The company plans to develop zervimesine for dementia with Lewy bodies psychosis, following the Phase 2 COG1201 (SHIMMER) study in 130 adults with mild-to-moderate DLB. It holds an end-of-Phase 2 meeting with the FDA for a Phase 3 program in Alzheimer's disease, and it reports Fast Track designation from the FDA for Alzheimer's disease. Its clinical trials have been funded primarily by grants from the National Institute on Aging, and it retains worldwide rights to zervimesine for all indications.
| Product or program | What it is | Stage |
|---|---|---|
| Zervimesine (CT1812) for Alzheimer's disease | Oral small molecule that protects neuronal synapses from pathogenic protein oligomers | Phase 2 (START); Phase 3 program planned |
| Zervimesine for DLB psychosis | Planned development program for psychosis in dementia with Lewy bodies | Planned |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $37.2 million | $41.7 million |
| Net income (loss) | -$23.5 million | -$34.0 million |
| Cash from operations | -$24.6 million | -$28.5 million |
| Cash and equivalents | $36.8 million | $25.0 million |
Cognition Therapeutics, Inc. trades under the ticker CGTX on NASDAQ.
Cognition Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Cognition Therapeutics, Inc. is 1455365. Its filings are on SEC EDGAR.
95,093,746 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Cognition Therapeutics, Inc. under United States.
Our directory classifies Cognition Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Cognition Therapeutics, Inc. is US19243B1026.
aibio.space lists Cognition Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, zervimesine, also known as CT1812, is an orally delivered small molecule designed to prevent oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein, from binding to neurons.
Zervimesine (CT1812) for Alzheimer's disease: Oral small molecule that protects neuronal synapses from pathogenic protein oligomers Stage: Phase 2 (START); Phase 3 program planned.
Zervimesine for DLB psychosis: Planned development program for psychosis in dementia with Lewy bodies Stage: Planned.
Cognition Therapeutics, Inc. reported a net loss of $23.5 million for the fiscal year ended Dec 31, 2025, and used $24.6 million of cash in operations, per its annual report to the SEC.
$37.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$34.0 million in cash at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 1.01,1.02). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio